Qualigen Therapeutics, Inc. (QLGN)
$
3.21
+0.17 (5.30%)
Key metrics
Financial statements
Free cash flow per share
-11.4364
Market cap
5.4 Million
Price to sales ratio
0
Debt to equity
0.0840
Current ratio
8.8291
Income quality
0.9825
Average inventory
0
ROE
-0.7297
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Qualigen Therapeutics, Inc. is a biotechnology company focused on developing innovative therapeutic products aimed at treating cancer and infectious diseases. The cost of revenue for the company is $0.00 showcasing its production and operational expenses. The operating expenses amount to $5,761,720.00 encompassing various operational costs incurred in the pursuit of its development goals. The financial data pertains to the fiscal year 2024 and the earnings per share (EPS) is reported at -$17.28 indicating the company's profitability on a per-share basis. Furthermore, the diluted EPS is -$17.28 accounting for potential share dilution, which provides a clearer picture of shareholder value. The company is currently advancing several clinical candidates, including QN-302 for pancreatic ductal adenocarcinoma, QN-247, a DNA-coated gold nanoparticle targeting a range of cancers, RAS-F, a small-molecule inhibitor designed to block RAS mutations and inhibit tumor formation, and the STARS blood cleansing system, which aims to remove tumor-produced compounds and viruses from patients' blood. Established in 1996, Qualigen Therapeutics is headquartered in Carlsbad, California. The stock of Qualigen Therapeutics is currently affordable at $2.84 making it a suitable option for budget-conscious investors. Despite its competitive positioning, the stock has a low average trading volume of 2,647,173.00 indicating lower market activity, which may reflect on its liquidity. With a market capitalization of $5,430,810.00 the company is classified as a small-cap player, highlighting its potential for growth within the industry. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape and driving innovation and growth within the Healthcare sector. As the company progresses in its development of groundbreaking therapies, it navigates the complexities of the biotechnology landscape while appealing to investors looking for opportunities in emerging markets.
What is Qualigen Therapeutics, Inc. (QLGN)'s stock forecast?
Analysts predict Qualigen Therapeutics, Inc. stock to fluctuate between $1.61 (low) and $8.81 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Qualigen Therapeutics, Inc.'s market capitalization?
As of 2025-11-18, Qualigen Therapeutics, Inc.'s market cap is $5,430,810, based on 1,691,841 outstanding shares.
How does Qualigen Therapeutics, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Qualigen Therapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Qualigen Therapeutics, Inc. (QLGN) stock?
To buy Qualigen Therapeutics, Inc. (QLGN) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for QLGN. Place an order (Market, Limit, etc.).
What is the best time to invest in Qualigen Therapeutics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Qualigen Therapeutics, Inc. stock ever split?
Qualigen Therapeutics, Inc.'s last stock split was 1:50 on 2024-11-05.
How did Qualigen Therapeutics, Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$17.28 | Growth: 602.44%.
Where can I find Qualigen Therapeutics, Inc.'s investor relations reports?
Visit https://qlgntx.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Qualigen Therapeutics, Inc.?
You can explore historical data from here
What is the all-time high and low for Qualigen Therapeutics, Inc. stock?
All-time high: $1,560 (2021-11-23) | All-time low: $1.61 (2025-08-13).
What are the key trends affecting Qualigen Therapeutics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
Dubai, UAE / Beijing, China, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics Inc. (NASDAQ: QLGN) (“Qualigen”, “QLGN” or the “Company”), a publicly-traded technology company majority owned by Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (“Faraday Future” or “FF”), today announced that it will rebrand as AIxCrypto following its stockholder meeting on November 12, 2025.
benzinga.com
Qualigen Therapeutics Inc. (NASDAQ:QLGN) shares exploded in Thursday's after-hours trading after the company partnered with digital asset firm BitGo to support its multi-asset cryptocurrency treasury strategy.
globenewswire.com
Carlsbad, CA, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) today announced a series of key leadership and governance changes aimed at strengthening its executive team, enhancing financial transparency, and supporting the Company's next phase of strategic growth.
globenewswire.com
QLGN is expected to rebrand as CXC10 soon, reflecting its new strategic direction around crypto and web3 business. LOS ANGELES, Sept.
globenewswire.com
LOS ANGELES, Sept. 21, 2025 (GLOBE NEWSWIRE) -- Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (“Faraday Future”, “FF” or “Company”), a California-based global shared intelligent electric mobility ecosystem company announced that it is strategically investing in public company Qualigen Therapeutics, Inc. (NASDAQ: QLGN), which will start a crypto and web3-related business. The announcement, which included numerous Company updates, occurred at its annual 919 event, held on Friday, Sept. 19, at its Los Angeles headquarters.
globenewswire.com
LOS ANGELES and CARLSBAD, Calif., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (“Faraday Future”, “FF” or “Company”), a California-based global shared intelligent electric mobility ecosystem company, and Qualigen Therapeutics, Inc. (NASDAQ: QLGN) ("QLGN"), jointly announced that they have entered into a securities purchase agreement (the “Agreement”) for a private investment in public equity (PIPE) in QLGN's common stock and preferred stock, and will start a crypto and web3-related business.
globenewswire.com
LOS ANGELES and CARLSBAD, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (“Faraday Future”, “FF” or “Company”), a California-based global shared intelligent electric mobility ecosystem company, and Qualigen Therapeutics, Inc. (NASDAQ:QLGN) ("QLGN"), jointly announced that they have entered into a securities purchase agreement (the “Agreement”) for a private investment in public equity (PIPE) in QLGN's common stock and preferred stock, and will start a in Crypto and web3-related business.
globenewswire.com
Carlsbad, CA, July 28, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN) ("Qualigen" or the "Company"), a life sciences company focused on developing platform treatments for adult and pediatric cancers with the potential for orphan drug designations, today announced that it has entered into definitive securities purchase agreements with several institutional and accredited investors for the sale of its Series A-3 Preferred Stock. The private placement closed on July 28, 2025. The Company issued and sold an aggregate of 4,500 shares of Series A-3 Preferred Stock, with a stated value of $1,000 per share, for aggregate gross proceeds of $4.5 million, before deducting placement agent fees and other offering expenses. The Series A-3 Preferred Stock is initially convertible into an aggregate of 1,607,143 shares of common stock of the Company at a conversion price of $2.80 per share, subject to adjustment in accordance with the terms of the Series A-3 Preferred Stock Certificate of Designation.
See all news
